Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521397 | 0.86 | KCNJ1 (0.42) | KCNJ1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL10123150 | 0.86 | KCNJ1 (0.42) | KCNJ1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL29859638 | 0.85 | KCNJ1 (0.41) | KCNJ1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL25804628 | 0.85 | KCNJ1 (0.41) | KCNJ1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL18397105 | 0.85 | KCNJ1 (0.41) | KCNJ1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL1070876 | 0.84 | P4HA1 (0.55) | MAPTALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL10034527 | 0.82 | CLK1 (0.39) | MAPTCLK1CLK2MAPK1RAB9A | |
| SCHEMBL12775299 | 0.82 | NNMT (0.55) | SMN1; SMN2L3MBTL1EPHX2 | |
| SCHEMBL934659 | 0.82 | TRPV4 (0.48) | KCNJ1MAPTSMN1; SMN2L3MBTL1MLYCD | |
| SCHEMBL3485657 | 0.82 | NAPRT (0.41) | MAPTALDH1A1CLK1CLK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2007129188-A1 | CYCLOPROPANECARBOXAMIDE COMPOUND | PFIZER JAPAN INC. (JP) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KCNJ1 1428/4885MAPT 1292/4885KMT2A 602/4885 |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KCNJ1 1428/4885MAPT 1292/4885KMT2A 602/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | KCNJ1 1227/4885MAPT 165/4885KMT2A 3607/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KCNJ1 1428/4885MAPT 1292/4885KMT2A 602/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | KCNJ1 1428/4885MAPT 1292/4885KMT2A 602/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | KCNJ1 84/4885MAPT 800/4885KMT2A 2606/4885 |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | KCNJ1 1428/4885MAPT 1292/4885KMT2A 602/4885 |
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KCNJ1 160/4885MAPT 3284/4885KMT2A 2365/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KCNJ1 151/4885MAPT 3269/4885KMT2A 2175/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KCNJ1 151/4885MAPT 3269/4885KMT2A 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.